ANNOVIS BIO (ANVS) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:ANVS - US03615A1088 - Common Stock
ANVS Key Statistics, Chart & Performance
The current stock price of ANVS is 3.85 USD. In the past month the price decreased by -18.28%. In the past year, price decreased by -22.29%.
ANVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About ANVS
Company Profile
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Company Info
ANNOVIS BIO
101 Lindenwood Drive, Suite 225
Malvern PENNSYLVANIA 19312 US
CEO: Maria Maccecchini
Employees: 8
Phone: 14848753192
ANNOVIS BIO / ANVS FAQ
Can you describe the business of ANNOVIS BIO?
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
What is the stock price of ANNOVIS BIO today?
The current stock price of ANVS is 3.85 USD. The price increased by 1.32% in the last trading session.
Does ANVS stock pay dividends?
ANVS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANVS stock?
ANVS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the ownership details for ANVS stock?
You can find the ownership structure of ANNOVIS BIO (ANVS) on the Ownership tab.
Can you provide the short interest for ANVS stock?
The outstanding short interest for ANNOVIS BIO (ANVS) is 12.75% of its float.
ANVS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ANVS. When comparing the yearly performance of all stocks, ANVS is one of the better performing stocks in the market, outperforming 93.17% of all stocks.
ANVS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANVS. The financial health of ANVS is average, but there are quite some concerns on its profitability.
ANVS Financial Highlights
Over the last trailing twelve months ANVS reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 60.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -144.77% | ||
| ROE | -189.15% | ||
| Debt/Equity | 0 |
ANVS Forecast & Estimates
10 analysts have analysed ANVS and the average price target is 14.03 USD. This implies a price increase of 264.29% is expected in the next year compared to the current price of 3.85.